anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a Prospective Observational Study. All new patients in chronic pain OPD are been administered BPI questionnaire as a standard of practice in our institute, in the language best understood by them e.g. English, Hindi, Marathi, Bengali. The participants will be asked to complete it once during their first visit to the pain clinic, before the start of treatment or ongoing treatment for pain (Baseline) and then during subsequent visits (Follow up). Most chronic pain patients are advised to follow-up by one to two weeks. Patients who are willing to participate in the study will be included after obtaining an informed consent. Data will be collected from BPI, Chronic Pain Record form and EMR and will be analyzed. Demographic data, diagnosis, pain data sheet, drug treatment as well as other form of therapies will be recorded. There will be no direct communication with the patient and data of quality of life will be retrieved from pain clinic records.

The Brief Pain Inventory (BPI) long form and short form questionnaire is a validated multidimensional pain assessment tool developed by Cleeland and Ryan. It is one of the most commonly used measures for assessing both pain severity and interference with functions in adults with cancer, thereby satisfying two recommendations (assessment of pain to include both intensity and interference) set by the Initiative on Methods, Measurements, and Pain Assessment in Clinical Trials (IMMPACT) group. It is brief, self administered, easily understood and can be administered to large numbers of patients,.

It contains three questions regarding pain intensity and seven regarding pain interference that are rated on an ordinal numerical scale with anchors of 0 (no pain/interference) to 10 (maximum pain/interference). Pain intensity is measured according to the worst pain experienced in the last three days, average pain in the last three days, and current pain. Pain interference assesses how that pain has affected general activity, mood, walking ability, normal work, relations with others, sleep, and enjoyment of life. The sum of the scores of the pain intensity items represents the summed pain intensity score and the sum of the scores on the pain interference items represents the summed interference score. In addition, the patient enters his pain localization on a body drawing and can give details of his current medication.
An anti-cancer medicine sustained-release agent containing 5-FU potentiating is sustained-release injection, which is made up of sustained-release micro-balloons and solvent. The sustained-release micro-balloons includes anticancer effective ingredient and sustained-release adjuvant, the solvent is common solvent or special solvent containing suspending agent. The anticancer effective ingredient contains 5-FU or the combination of 5-FU with the potentiating agent of 5-FU chosen from hormones anti-cancer drugs and/or blood vessel inhibitor. The sustained-release adjuvant is chosen from polylactic acid, polyglycolic acid, glycolic acid co-polymer, and one or the combination of ethylene acetic acid ethyenyl ester co-polymer, polifeprosan, FAD and sebacic acid co-polymer. The suspending agent is chosen from sodium carboxymethylcellulose, etc. The sustained-release micro balloons can also be produced into sustained-release implantation agent which is implanted into knub or injected around tumour or deposited around tumour. The sustained-release agent can be used alone or used with chemotherapy medicament and non-operative treatment such as radiotherapy.
Mild local hyperthermia with a certain temperature range has been successfully used in treatment of some diseases. It has been applied in the treatment of some neoplasm, fungal and HPV infections. Previous studies regarding viral warts and sporotrichosis found that in patients with multiple lesions, the clearance of the target lesion is commonly followed by clearance of other distant lesions, a phenomenon suggesting that local hyperthermia could aid in establishing a specific immune response to eliminate pathogenic microorganisms. Investigators speculate that mild local hyperthermia was a potential treatment for onychomycosis. A prospective single arm clinical trial was conducted to evaluate the effectiveness and safety of mild local hyperthermia in the treatment of onychomycosis. Participants with onychomycosis with at least 2 nails involved were included. The treatment effect of the treated and the untreated nail onychomycosis was measured after 6 months and 12 months of initial treatment.
East Carolina University, along with established community partners, is implementing a community-based and culturally-tailored intervention to reduce diabetes disparities in 200 rural African American women with uncontrolled diabetes using our unique behaviorally-centered small changes approach to diabetes self-management, delivered by community health workers. The focus is on moderation and patient-selected small changes in eating, activity, and care management that decrease feelings of deprivation and failure and increase feelings of confidence and success. The intervention is specifically tailored to overcome psychosocial and environmental barriers to behavioral change through a strong focus on emotional, cultural, and social factors related to eating, activity, and medications. Objectives for the proposed project are to: 1) implement and evaluate the effectiveness of this tailored small changes intervention; 2) examine the impact of this approach on psychological mediators of behavioral choices in diabetes; 3) implement and evaluate public policy and built environment advocacy strategies; and 4) build, sustain, and disseminate a business-sustainable care model. The study will be a randomized prospective trial comparing the small changes intervention, delivered in 16 sessions by community health workers, to a control group receiving 16 mailings of diabetes educational materials. We hypothesize that there will be a greater improvement in behavioral choices and glycemic control in the intervention group compared to the control group.
PCT No. PCT/GB79/00141 Sec. 371 Date Apr. 23, 1980 Sec. 102(e) Date Apr. 23, 1980 PCT Filed Aug. 16, 1979 PCT Pub. No. WO80/00412 PCT Pub. Date Mar. 20, 1980.A pasteurella vaccine e.g. for use with cattle or particularly sheep, comprises antigenic material derived from the A1 and A2 serotypes of Pasteurella haemolytica, the A1 serotype antigenic material comprising capsular extract, e.g. especially salicylate extract, and the A2 serotype antigenic material comprising heat-killed whole organisms, and a process for the production of a pasteurellosis vaccine comprises preparing said antigenic material from P. haemolytica organisms and formulating the antigenic material into a vaccine, e.g. especially an aluminium hydroxide gel/oil adjuvant vaccine. Also a method for use in agricultural animal husbandry for the prevention and control of pasteurellosis in sheep, cattle and other animals comprises vaccinating the animals with a vaccine according to the invention.
A computer implemented system to assist a user includes a cognitive computation module which can speak to, listen to and/or see. The system can assist in patient care delivery, driving, providing security, customer support and identity verification. It may be configured in a processor of the computing device which receives text data input after converting speech into text. The received text data is analysed by the module using an artificial intelligence and/or decision rules modules. The modules may create a response of text output which is converted to speech data using text to speech module and sent to the communication module to speak out. It identifies posture of human body, or the face of a human or a user using computer connected camera and also receives input from other sensors or devices connected to the computer and sends input to the cognitive communication module for analysis and response.
A composition providing electrically conductive adhesive hydrogels used as skin contact adhesives and an electrical interface for disposable medical devices. The hydrogels are cationic acrylates and are mad e from acrylic esters of quaternary chlorides and/or sulfates or acrylic amides of quaternary chlorides. The present hydrogels are formed by free radical polymerization in the presence of water by ultraviolet curing with initiator and multifunctional cross-linking agent, a nd include a buffer system to prevent discoloration, hydrolysis of and improve shelf-life of the hydrogels. Other additives may be added to the hydrogels either before or after curing, depending on the intended end use. The present hydrogels hydrate a subject's skin, wet around skin surface hair and protect against burning of a subject due to electrical stimulation through the hydrogel. The hydrogels, cohesiveness enables direct hydrogel-to-hydrogel contact and storage, yet remain readily separable. The hydrogels may be presented in a formula which is noncorrosive to aluminum in contact therewith, and pass standards testing for biocompatibility and electrical properties.
Methods are provided for allowing patients, health care practitioners and other service providers to have remote access to electronic medical records of a patient stored on a computer network by receiving, from the provider, a request for requesting access to the electronic medical record and providing a provider information, a consent validation service (CVS) attribute, a patient information, and a purpose of use, the provider information selected from a group consisting of a provider ID, a provider location, a provider department, and the purpose of use, the CVS attribute selected from a group consisting of a patient name, the provider ID, the provider location, the provider department, and the purpose of use, the patient information selected from a group consisting of a patient ID, a password, a passphrase, and a key; authenticating the provider through the provider information; authenticating the provider by validating the patient information; confirming a patient specific consent protocol based on: the CVS attribute; the patient information; and the purpose of use; and establishing a connection for the access to the electronic medical record for the provider in response to authenticating the provider and confirming the patient specific consent protocol. (FIG. 3) oil Start Patent presents -301 to Healthcare provider Patient supplies the web address of Rernote Electronic /0 Medical Record Access Service Provider identifies ,303 hirnseftherself Portal locates provideron MPR, asks for -- 304 Purpose-of-use, Departmnent Nd o = Provide fills otdetaied -30 < >Purpose-f-Use, Departrnent Yes Enter Patient ID and Passphrase (if avail) Yes No38 4Pasphrase Validate Patient ID Validate Patient lDI 307 Not Valid Passphrase (Result Not Valid + VldId 309 Result Performn Provider Authentication Valid Success Reut Fail Verify Patiert Identity/ 31 Enter reason onDeyacs Access screen Validate access to the patient info. (CVS check) Den-y -312 <ResultDeyacs Portal login to EMR ? 313 Proxy connection to _314 the EMR C: LD.Fig. 3
Storage

Store PYLARIFY at controlled room temperature (USP) 20°C to 25°C (68°F to 77°F). PYLARIFY does not contain a preservative. Store PYLARIFY in the original container with radiation shielding. The expiration date and time are provided on the container label. Use PYLARIFY within 10 hours from the time of end of synthesis.

Handling

This preparation is approved for use by persons under license by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State.
The present invention relates to a chemically modified mutant protein including a cysteine residue substituted for a residue other than cysteine n a precursor protein, the substituted cysteine residue being subsequently modified by reacting the cysteine residue with a glycosylated thiosulfonate. Also a method of producing the chemically modified mutant protein is provided. The present invention also relates to a glycosylated methanethiosulfonate. Another aspect of the present invention is a method of modifying the functional characteristics of a protein including providing a protein and reacting the protein with a glycosylated methanethiosulfonate reagent under conditions effective to produce a glycoprotein with altered functional characteristics as compared to the protein. In addition, the present invention relates to methods of determining the structure-function relationships of chemically modified mutant proteins. The present invention also relates to synthetic methods for producing thio-glycoses, the thio-glycoses so produced, and to methods for producing glycodendrimer reagents.
1411736 Treating cocoa fruit U DREVICI and N DREVICI 20 July 1972 [23 July 1971] 44512/74 Divided out of 1411591 Headings A2B and A2Q An animal feed composition is produced by (1) treating unopened cocoa fruit with a preservative so as to neutralize any abnoxious substances on the surface and prevent further liquification of the peel, (2) opening the fruit, (3) removing the beans, (4) comminuting the pods and (5) mixing the comminuted pods with 2-4 weight % of a fatty material. Preservatives specified include sorbic acid, sulphur dioxide, chlorine, formaldehyde, ozone, methyl formate, diphenyl, ammonia, sodium o-phenyl phenolate, nitrogen trichloride, potassium sorbate, sodium hypochlorite, calcium hypochlorite, sodium disulphite and potassium disulphite. Fatty materials specified include suet, lard, acidified soap stock and vegetable oil. In one embodiment freshly harvested cocoa fruit are treated with potassium sorbate, kiln dried and opened, the beans are removed and the flesh is ground and mixed with suet in a roller mill. In supplementary procedures the juice may be expressed from the pods, the pods may be dried and, after comminution, sieved to remove fibres. The product may be mixed with proteinaceous waste-waters from food processing plants and finally pelleted.
PROBLEM TO BE SOLVED: To obtain a dental composition suitable for a dental surface coating material, capable of reducing a factor by which a dental resin cement or the like is inhibited from polymerizing when cured, by compounding a water-soluble cellulose and a water-soluble organic solvent. SOLUTION: This dental composition comprises 100 pts.wt. of a mixture comprising (A) a water-soluble cellulose in an amount of 3-20 wt.% and (B) a water-soluble organic solvent in an amount of 97-80 wt.% and, if necessary, 0.05-10 pts.wt. of (C) one or more kinds of components selected from a polymerization catalyst, a polymerization promoter, a reducing agent, etc. Hydroxypropylcellulose having a substitution degree (indexing how many groups among the three hydroxyl groups existing in a glucose unit are esterified or etherified on an average) of 1.5-2.0 or the like is preferably used as the component A. 1,2-Propanediol, 1,3-butanediol, ethylene glycol, glycerin or the like is preferably used as the component B.
PCT No. PCT/US94/06273 Sec. 371 Date Jan. 9, 1995 Sec. 102(e) Date Jan. 9, 1995 PCT Filed Jun. 3, 1994 PCT Pub. No. WO94/29449 PCT Pub. Date Dec. 22, 1994In accordance with the present invention, there are provided nucleic acids encoding human metabotropic glutamate receptor subtypes and the proteins encoded thereby. In a particular embodiment, the invention nucleic acids encode mGluR1, mGluR2, mGluR3 and mGluR5 subtypes of human metabotropic glutamate receptors. In addition to being useful for the production of metabotropic glutamate receptor subtypes, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits. In addition to disclosing novel metabotropic glutamate receptor subtypes, the present invention also comprises methods for using such receptor subtypes to identify and characterize compounds which affect the function of such receptors, e.g., agonists, antagonists, and modulators of glutamate receptor function.
Antigen-antibody assaying of prostaglandin E2 contg. - bio-samples is improved, when a sequential satn. reaction-based on mono- 125-tyrosine-methyl-ester-deriv. of prostaglandin E2 as isotopic marking indicator and on a specific PGE2 antibody as protein-fixative-replaces a previously used method of a satn. reaction in a state of equilibrium. New equilibrium conditions are maintained for the incubation of inactive antigen and antibodies, but the incubation of antibodies and radioligands occurs under. non-equalibrium conditions. This movel method increases the sensitivity of the data three-four fold compared to equilibrium state radio-immunological assaying. - Reaction parameters are optimised in incubation processes i.e. reaction periods, temps. and antibody concns. - Reagents, are identical to those used in previous detections.
Teratogenic Effects

Dextroamphetamine sulfate has been shown to have embryotoxic and teratogenic effects when administered to A/Jax mice and C57BL mice in doses approximately 41 times the maximum human dose. Embryotoxic effects were not seen in New Zealand white rabbits given the drug in doses 7 times the human dose nor in rats given 12.5 times the maximum human dose. There are no adequate and well-controlled studies in pregnant women. Amphetamine sulfate tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nonteratogenic Effects 

Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight. Also, these infants may experience symptoms of withdrawal as demonstrated by dysphoria, including agitation, and significant lassitude.
The present invention belongs to Chinese medicine ointment for treating burns and scalds and the manufacture method of the ointment. The Chinese medicine ointment has the components of the weight proportion: 1 portion of Chinaroot greenbrier rhizomes, 1 portion of Chinaroot greenbrier leaves, 1 to 5 portions of coptis, 1 to 6 portions of sanguisorba roots and 2 to 8 portions of vaseline. A proper amount of menthol, borneol and tea oil can also be added to the components. The Chinaroot greenbrier rhizomes and the sanguisorba roots are respectively and completely calcined into carbon. The Chinaroot greenbrier leaves and the coptis are dried. The menthol and the borneol are taken to be evenly mixed with the carbon, the Chinaroot greenbrier leaves and the coptis. Then, the mixture is ground into powder. The tea oil and the medicine powder are added to and evenly mixed with the vaseline after the vaseline is dissolved. The present invention has the functions of good curative effect, safety, low cost and no poison.
BACKGROUND: A previous single-center study of patients with myocardial infarction (MI) showed that platelet FcγRIIa (pFCG) can distinguish patients at higher and lower risk of subsequent MI, stroke, and death.
OBJECTIVES: The authors performed an 800-patient 25-center study to validate the prognostic implications of pFCG.
METHODS: Patients with type 1 MI (ST-segment elevation and non-ST-segment elevation) were enrolled in a prospective noninterventional trial during their index hospitalization. Enrolled patients had at least 2 of the following characteristics: age ≥65 years, multivessel coronary artery disease, previous MI, chronic kidney disease, or diabetes mellitus. Flow cytometry was used to quantify pFCG at a core laboratory. A predefined threshold was used to identify high and low pFCG. Patients were queried every 6 months by telephone with a standardized questionnaire. Events were confirmed by review of medical records.
RESULTS: Treatment with antithrombotic therapy (aspirin, P2Y12 inhibitors, and anticoagulants) was similar in patients with high and low pFCG. The primary composite endpoint (MI, stroke, death) occurred more frequently in patients with high pFCG (HR: 2.09; 95% CI: 1.34-3.26; P = 0.001). Among individual components of the composite, both death (HR: 2.57; 95% CI: 1.50-4.40; P = 0.001) and MI (HR: 3.24; 95% CI: 1.64-6.37; P = 0.001) were more frequent in patients with high pFCG.
CONCLUSIONS: Quantifying pFCG identifies patients at higher and lower risk of subsequent cardiovascular events. This prognostic information will be useful in clinical decisions regarding the intensity and duration of antiplatelet therapy. (Assessment of Individual Risk of Cardiovascular Events by Platelet FcγRIIa; NCT05175261).
The activation of cyclin dependent kinase 5 (Cdk5) depends on the binding of its neuronal specific activator Nck5a. The minimal activation domain of Nck5a has been experimentally determine comprise acid residues 150 to 291 of the protein. It has been demonstrated that a 28 residue peptide encompassing amino acid residues Ala 146 to Asp 173 of Nck5a is capable of binding Cdk5 and hence resulting in the inhibition of its Kinase activity. Additionally, this peptide could also inhibit Cdk2 with a similar potency as it does to Cdk5. The direct competition experiments showed that the Nck5a inhibitory peptide does not compete with Nck5a for Cdk5 or cyclin A for Cdk2. Steady state kinetic analysis indicated that the Nck5a peptide acts as a non-competitive inhibitor of Cdk5/Nck5a complex with respect to its substrate. The structure of the peptide in solution as determined by the methods of circular dichroism and two-dimensional 1H NMR spectroscopy have been performed in order to understand the molecular basis of kinase inhibition by the peptide. A segment of the peptide, corresponding to amino acid resides Ser149 to Arg169 adopts an amphipathic alpha-helical structure in solution. Four Leu residues and one Phe residue clustered on the hydrophobic face of the helix, and this hydrophobic face is likely to be the contact area when the peptide binds and inhibits both Cdk5 and Cdk2. Mutational experiments have also indicated that the C-terminal end of the peptide contributes to the inhibition of Cdk5 and Cdk2.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to obstetrics and ginecology, and deals with treatment of fetoplacental insufficiency (FPI). For this purpose in addition to traditional drug therapy, 10 ml of cytoflavin diluted in 200.0 ml of 0.9% solution of sodium chloride is introduced to pregnant women with FPI intravenously during 4 days. Introduction is performed drop-by drop at rate 2 ml per minute in terms of undiluted cytoflavin. During 3 following days cytoflavin is introduced in amount 5 ml per day in said mode. ^ EFFECT: invention ensures increase of FPI treatment due to claimed mode of cytoflavin introduction with reduction of course dose and treatment duration without manifestation of side effects. ^ 2 ex
Chimeric fusion proteins comprising  Neisseria  transferrin binding proteins (Tbps) from, for example,  N. gonorrhoeae  and/or  N. meningitidis  are provided. The fusion proteins elicit an antibody response in the mucosa of the urogenital and/or oropharynx tract, as well as in the serum. The resulting serum antibodies are cross-bactericidal against heterologous bacterial strains. The chimeric proteins also comprise a mucosal adjuvant such as a toxin subunit, e.g. the B subunit of cholera toxin or of  Escherichia coli  heat labile toxin II. Methods of inhibiting the growth of  Neisseria  species on mucosal surfaces of a mammal by either administering the fusion proteins of the invention, or antibodies directed to the fusion proteins of the invention, to the mammal.